NCT00813787

Brief Summary

The purpose of this study is to see if a specialized imaging technique using MRI called multi-exponential T2 component analysis can reliably differentiate between normal brain and brain tumour.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 23, 2008

Completed
1 month until next milestone

Study Start

First participant enrolled

February 1, 2009

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
Last Updated

October 3, 2014

Status Verified

October 1, 2014

Enrollment Period

6.2 years

First QC Date

December 19, 2008

Last Update Submit

October 1, 2014

Conditions

Keywords

Magnetic Resonance ImagingGlioma

Outcome Measures

Primary Outcomes (1)

  • T2 characteristics of glioma tissue versus normal

    Before radiotherapy treatment begins

Study Arms (2)

A. glioma

A. glioma population

B. Normal brain

B. Normal brain

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A. Any glioma patient who recieves treatment at our clinic (Cross Cancer Institute) who agrees to take part in the study. B. Any normal volunteer who agrees to take part in the study.

You may qualify if:

  • Eighteen years of age or older
  • Clinical subjects must have not yet begun radiation therapy
  • Must have signed our study-specific consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

RECRUITING

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Officials

  • Keith Wachowicz, PhD

    AHS Cancer Control Alberta

    STUDY CHAIR

Central Study Contacts

Keith Wachowicz, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 19, 2008

First Posted

December 23, 2008

Study Start

February 1, 2009

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

October 3, 2014

Record last verified: 2014-10

Locations